Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Biodesix Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Biodesix şirketinin kazançları yıllık ortalama -15.8% oranında azalırken, Healthcare sektörünün kazançları yıllık 6.2% oranında artan oldu. Gelirler yıllık ortalama 6.9% oranında azalan oldu.

Anahtar bilgiler

-15.8%

Kazanç büyüme oranı

95.8%

EPS büyüme oranı

Healthcare Sektör Büyümesi	8.5%
Gelir büyüme oranı	-6.9%
Özkaynak getirisi	-122.8%
Net Marj	-73.1%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Sep 24

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

Jun 12

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Mar 03

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Jan 04

Need To Know: Analysts Just Made A Substantial Cut To Their Biodesix, Inc. (NASDAQ:BDSX) Estimates

Nov 25

Bearing In On Biodesix

Sep 13

Gelir ve Gider Dağılımı

Biodesix nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGM:BDSX Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	61	-45	72	8
31 Mar 24	55	-47	69	9
31 Dec 23	49	-52	67	10
30 Sep 23	44	-63	68	12
30 Jun 23	42	-66	67	13
31 Mar 23	41	-69	66	13
31 Dec 22	38	-65	61	13
30 Sep 22	36	-58	58	12
30 Jun 22	31	-56	57	13
31 Mar 22	32	-52	53	13
31 Dec 21	55	-43	51	13
30 Sep 21	74	-34	49	13
30 Jun 21	77	-32	43	12
31 Mar 21	69	-29	39	11
31 Dec 20	46	-31	35	11
30 Sep 20	27	-33	29	10
30 Jun 20	22	-34	30	10
31 Mar 20	23	-33	31	11
31 Dec 19	25	-31	31	10
31 Dec 18	20	-26	26	8

Kaliteli Kazançlar: BDSX şu anda kârlı değil.

Büyüyen Kar Marjı: BDSX şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: BDSX kârlı değildir ve zararlar son 5 yılda yılda 15.8% oranında artmıştır.

Büyüme Hızlandırma: BDSX 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: BDSX kârlı olmadığından, geçmiş yıl kazanç büyümesinin Healthcare sektörüyle ( 8% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: BDSX hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -122.75% ) sahiptir.

Biodesix Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Biodesix, Inc. to Report Q2, 2024 Results on Aug 07, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. to Report Q4, 2023 Results on Mar 01, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?

Biodesix, Inc. Raised Revenue Guidance for the Year 2024

Biodesix, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

New major risk - Shareholder dilution

Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. to Report Q1, 2024 Results on May 08, 2024

Biodesix, Inc., Annual General Meeting, May 21, 2024

Biodesix, Inc. announced that it expects to receive $34.999422 million in funding

Biodesix, Inc. has completed a Follow-on Equity Offering in the amount of $20.000607 million.

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2024

Biodesix, Inc. to Report Q4, 2023 Results on Mar 01, 2024

President notifies of intention to sell stock

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Biodesix, Inc. Enhances Access to Nodify Lung Testing with Launch of New Blood Draw Method

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2023

Biodesix, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New major risk - Share price stability

Biodesix, Inc. Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

Independent Director recently bought US$217k worth of stock

Biodesix, Inc. Announces Presentation of New Nodify XL2(R) Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

Consensus EPS estimates upgraded to US$0.68 loss

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. to Report Q2, 2023 Results on Aug 07, 2023

It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

Biodesix, Inc. Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating That the Nodify XL2 Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

Biodesix, Inc. Receives Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services

Biodesix Completes Enrollment of Insight Study Assessing Clinical Utility of the Veristrat®? Blood-Based Host Immune Classifier

Biodesix, Inc. Announces Resignation of Ryan Siurek as Chief Accounting Officer, Effective July 3, 2023

Independent Director recently bought US$65k worth of stock

Biodesix, Inc. Announces New Clinical Utility Evidence for the Nodify XL2 Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Independent Director recently bought US$125k worth of stock

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify Xl2® Test

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify Xl2® Test

Biodesix, Inc. Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors and Audit Committee of the Board, Effective January 3, 2023

Independent Director recently bought US$148k worth of stock

Biodesix, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Price target decreased to US$5.00

Biodesix, Inc. Presents New Data from the Insight Study At the 2022 Society for Immunotherapy of Cancer 37Th Annual Meeting

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Provides Earnings Guidance for the Year 2022

Biodesix, Inc. to Report Q3, 2022 Results on Nov 03, 2022

A Second Look At Biodesix

Biodesix, Inc. Provides Revenue Guidance for the Third Quarter 2022

Biodesix expects Q3 revenue above the consensus

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2022

Biodesix GAAP EPS of -$0.40 beats by $0.07, revenue of $10.95M beats by $2.12M

Biodesix, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Biodesix, Inc.(NasdaqGM:BDSX) dropped from Russell 2000 Growth Index

Biodesix, Inc. Obtains Medicare Coverage for the Nodify CDT Lung Nodule Test

Biodesix: Bad Diagnosis

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2022

Price target decreased to US$9.00

High number of new directors

Consensus forecasts updated

Independent Director recently bought US$5.0m worth of stock

Biodesix, Inc., Annual General Meeting, May 24, 2022

Consensus revenue estimates increase by 10%